NASDAQ:SGMO - Sangamo Therapeutics Stock Price, Forecast & News

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

Sangamo Therapeutics Inc (NASDAQ:SGMO) posted its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.10. The biopharmaceutical company had revenue of $21.96 million for the quarter, compared to analyst estimates of $12.16 million. Sangamo Therapeutics had a negative net margin of 159.12% and a negative return on equity of 30.33%. The firm's revenue was down 6.8% on a year-over-year basis. During the same period in the prior year, the company earned ($0.13) earnings per share. View Sangamo Therapeutics' Earnings History.

Sangamo Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Sangamo Therapeutics.

3 brokers have issued twelve-month price objectives for Sangamo Therapeutics' shares. Their forecasts range from $11.00 to $16.00. On average, they anticipate Sangamo Therapeutics' share price to reach $13.50 in the next twelve months. This suggests a possible upside of 81.9% from the stock's current price. View Analyst Price Targets for Sangamo Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sangamo Therapeutics.

Headlines about SGMO stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sangamo Therapeutics earned a coverage optimism score of 1.4 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Sangamo Therapeutics.

Some companies that are related to Sangamo Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Brainstorm Cell Therapeutics (BCLI), Micron Technology (MU), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Novavax (NVAX), Zuora (ZUO), Gilead Sciences (GILD), Alibaba Group (BABA) and Netflix (NFLX).

Sangamo Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include State Street Corp (4.15%), Credit Suisse AG (2.13%), FMR LLC (1.74%), Pictet Asset Management Ltd. (1.16%), Goldman Sachs Group Inc. (1.11%) and Alexandria Capital LLC (0.83%). Company insiders that own Sangamo Therapeutics stock include Curt A Herberts III, Edward R Conner, H Stewart Parker, Kathy Yi, Saira Ramasastry and Steven J Mento. View Institutional Ownership Trends for Sangamo Therapeutics.

SGMO stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., FMR LLC, State Street Corp, UBS Group AG, Bank of America Corp DE, Rafferty Asset Management LLC, Candriam Luxembourg S.C.A. and Bailard Inc.. View Insider Buying and Selling for Sangamo Therapeutics.

SGMO stock was purchased by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Creative Planning, Marshall Wace LLP, State of New Jersey Common Pension Fund D, Panagora Asset Management Inc., Cubist Systematic Strategies LLC, Tocqueville Asset Management L.P. and Alexandria Capital LLC. View Insider Buying and Selling for Sangamo Therapeutics.

Shares of SGMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SGMO stock can currently be purchased for approximately $7.42.

Sangamo Therapeutics has a market capitalization of $860.27 million and generates $84.45 million in revenue each year. The biopharmaceutical company earns $-68,330,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Sangamo Therapeutics employs 302 workers across the globe.View Additional Information About Sangamo Therapeutics.

The official website for Sangamo Therapeutics is http://www.sangamo.com/.

Sangamo Therapeutics' mailing address is 501 CANAL BLVD, RICHMOND CA, 94804. The biopharmaceutical company can be reached via phone at 510-970-6000 or via email at [email protected]